Krystal Biotech, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KRYS research report →
Range $361 – $474
Price Chart
About the company
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa.
- CEO
- Krish S. Krishnan
- IPO
- 2017
- Employees
- 295
- HQ
- Pittsburgh, PA, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a longer-term corrective phase after trading well below its 52-week high of 382.54 and under its 200-day average of 309.71. The setup is still constructive versus the 52-week low of 202.99, but the multi-month trend has not fully reclaimed its prior uptrend.
Street sentiment stays firmly positive, with a Buy consensus and an average target of 418.4, well above the current share price. Recent updates have mostly been target raises or reiterated bullish calls, including Citi at 416, Goldman Sachs at 441, and Jefferies at 474, which keeps the bias constructive.
The earnings profile is strong, with KRYS beating EPS in 5 of the last 8 quarters and posting an 11.4% beat in the latest report. Next-year EPS is still expected to rise to 9.2279 from 7.36 TTM, so shareholders should watch for continued execution and guidance that supports that path.
The pattern is mixed but leans to net selling, driven by two discretionary sales from the President of R&D and director, Suma Krishnan. The other recent director awards and the gift transfer are non-discretionary noise, so the main signal is limited insider selling rather than broad conviction buying.
Profitability remains elite, with a 94.3% gross margin, 48.41% operating margin, and 47.91% net margin. Growth is still healthy at 30.2% revenue growth year over year, while the balance sheet is strong with $827.8 million in cash against just $9.34 million of debt and $818.5 million in net cash.
KRYS screens as a premium biotech with commercial profitability and a much cleaner balance sheet than most peers. The valuation remains rich at 37.29 times earnings, but that multiple is supported by high margins, positive cash generation, and a commercial-stage asset base.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.15B
- P/E
- 40.84
- Fwd P/E
- 40.06
- PEG
- 3.65
- P/S
- 19.72
- P/B
- 6.45
- EV/EBITDA
- 34.95
- Div Yield
- 0.00%
- Gross Margin
- 93.36%
- Op Margin
- 48.44%
- Net Margin
- 47.91%
- ROE
- 17.02%
- ROIC
- 13.70%
Latest fiscal year · YoY change
- Revenue
- $389.13M+33.9%
- Gross Profit
- $360.36M+33.2%
- Op Income
- $161.29M
- Net Income
- $204.83M+129.7%
- EPS
- $7.08+126.9%
- OCF Growth
- +62.7%
- FCF Growth
- +58.5%
- 52W High
- $382.54
- 52W Low
- $203.35
- 50D MA
- $323.25
- 200D MA
- $310.29
- Beta
- 0.50
- RSI (14)
- 50
- Avg Volume
- 285.78K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Krystal Biotech delivered another strong quarter with VYJUVEK revenue growth, solid profitability, $1.2 billion in cash and investments, and multiple pipeline updates that pushed several readouts later while management remained upbeat.· November 2, 2026
- Q3 VYJUVEK revenue was $127.3 million, up 30% year over year, with diluted EPS of $2.05.
- Global gross margin was 94% versus 96% a year ago; the company also ended September with $1.2 billion in cash and investments.
- Management authorized a new share repurchase program of up to $400 million to be deployed over the next 2 years.
- International VYJUVEK growth continued, with Germany pricing completed, Italy pricing completed, France progressing, Spain expected by year-end, and Japan launch momentum building.
- Pipeline readouts were pushed out, but management said the studies are progressing well and highlighted encouraging Gorlin syndrome data plus ongoing work in HHD, ocular DEB, CF, NK, and NSCLC.
Net revenue from global VYJUVEK sales was $127 million in Q3, up 30% from $97.8 million in the prior-year quarter; U.S. net revenue was $95.3 million and international revenue was $32 million. Gross margin was 94% versus 96% a year ago, cost of goods sold was $7.6 million versus $4.3 million, R&D was $14.9 million versus $14.6 million, and G&A was $33.7 million versus $37.6 million. Net income was $63.1 million, or $2.13 per basic share and $2.05 per diluted share, versus $79.4 million and $2.74/$2.66 last year. For the full year, management revised non-GAAP R&D and SG&A guidance down to $155 million to $165 million from $175 million to $195 million. The company ended September with more than $1.2 billion in cash and investments and announced a share repurchase authorization of up to $400 million over the next 2 years.
Krish Krishnan framed the quarter as evidence that Krystal has built a profitable commercial business with resources to fund both global expansion and a broad pipeline. He emphasized that VYJUVEK is now generating meaningful international traction and that pricing agreements in major markets improve visibility for future growth. On the pipeline, he highlighted the Gorlin syndrome results as a strong foundation for FDA discussions and said the company is comfortable returning capital because of the strength of the balance sheet and revenue base. His tone was confident and constructive, while acknowledging that some clinical readouts will take longer than originally expected.
Kathryn Romano said global VYJUVEK sales of $127 million were up 30% year over year, with the increase driven by Europe and Japan launches. She noted gross margin of 94% versus 96% last year, explaining the decline was partly due to higher sales in Europe and Japan before those regions benefit from U.S.-optimized manufacturing efficiencies, plus the prior-year benefit from lower-cost R&D batches. She also cited lower G&A of $33.7 million, helped by insurance proceeds and lower legal, professional services, and marketing costs. On capital allocation, she said cash and investments now exceed $1.2 billion and reiterated disciplined spending while preserving flexibility for the new buyback.
Analysts focused heavily on why several clinical programs are taking longer and whether management would increase R&D spending to accelerate enrollment. Krish said the company would invest more if additional spending would directly speed enrollment or site activation, but emphasized that the buyback was approved only because management believes VYJUVEK cash generation and balance-sheet strength are sufficient to support both the pipeline and shareholder returns. Questions on ocular DEB and NK centered on enrollment friction; management said ocular DEB’s delays were mostly due to patient withdrawals from travel/compliance issues and that top-line data should come in the first half of 2027, while NK enrollment has been slowed by strict inclusion criteria and site activation delays but is expected to complete in 2027. Analysts also asked about Japan adoption and France pricing timing; management said Japan should benefit once the prescription restriction eases, and France’s negotiations are proceeding on a typical timetable with no unusual issues.
The call showed a profitable commercial asset with continued U.S. demand, expanding prescriber depth, and growing international access. Management also pointed to multiple pipeline shots on goal, especially the encouraging Gorlin data and ongoing progress in ocular DEB, HHD, CF, NK, and NSCLC, while retaining a large cash balance and authorizing a buyback.
Several pipeline milestones were pushed out, including NK and CF timing, and management acknowledged that some studies are moving more slowly than initially expected. International revenue still depends on continued pricing and reimbursement progress across additional countries, and the company flagged enrollment challenges from strict trial criteria, site delays, and patient compliance issues in some programs.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 79.8%
- Shares Outstanding
- 29.63M
- Float Shares
- 23.66M
of shares held by institutions
443 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for KRYS, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Chris JacobsHouse · NY27 | Buy | Dec 12, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 4.44M | ▲ 21.57K |
| Blackrock, Inc. | 3.59M | ▼ 590.80K |
| Avoro Capital Advisors LLC | 2.89M | 0 |
| Vanguard Group Inc | 2.78M | ▼ 13.36K |
| State Street Corp | 1.42M | ▲ 68.97K |
| Vanguard Portfolio Management LLC | 1.29M | ▼ 288.05K |
| Vanguard Capital Management LLC | 1.20M | ▼ 43.88K |
| Soleus Capital Management, L.P. | 1.14M | ▲ 200.45K |
| Geode Capital Management, LLC | 811.74K | ▲ 112.74K |
| Capital World Investors | 779.26K | ▲ 1.42K |
| Vestor Capital, LLC | 700.91K | 0 |
| Hood River Capital Management LLC | 671.99K | ▲ 8.61K |
Held by 511 ETFs
Biggest fund positions in KRYS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 12, 26 | ROSSI DINO A | other | 3,500 |
| Sep 14, 26 | ROSSI DINO A | other | 1,187 |
| Sep 14, 26 | ROSSI DINO A | other | 471 |
| Sep 14, 26 | Sutherland Everett Rand | other | 1,187 |
| Sep 14, 26 | Sutherland Everett Rand | other | 471 |
| Sep 14, 26 | Mazzacco Catherine | other | 1,187 |
| Sep 14, 26 | Mazzacco Catherine | other | 471 |
| Sep 14, 26 | Mason Christopher | other | 1,187 |
| Sep 14, 26 | Mason Christopher | other | 471 |
| Sep 14, 26 | JANNEY DANIEL | other | 1,187 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KRYS coverage
Recent articles, reports, and earnings notes.

Krystal Biotech (KRYS): VYJUVEK Growth Funds Pipeline
Krystal Biotech pairs a profitable commercial launch with a deep gene-therapy pipeline, but valuation leaves less room for execution missteps. VYJUVEK is driving strong revenue growth while multiple programs advance toward key clinical milestones.

Krystal Biotech's Q2 beat was not enough to save the stock
KRYS's 8.4% post-earnings drop says the market is pricing single-product risk harder than near-term growth. Vyjuvek is scaling, but a 21.23x sales multiple leaves little room for pipeline delays or reimbursement friction.

Krystal Biotech (KRYS): VYJUVEK Growth vs. Rich Valuation
Krystal Biotech is now a profitable commercial biotech, driven by VYJUVEK’s rapid adoption and a deep pipeline of 2026 catalysts. The stock’s strong fundamentals are offset by a premium valuation, supporting a Hold view.
Want a deeper read on KRYS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Krystal Biotech, Inc. - KRYS
prnewswire.com · Nov 19
KRYS Investors Have Opportunity to Join Krystal Biotech, Inc. Fraud Investigation with SBS Law
businesswire.com · Nov 19
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Krystal Biotech, Inc. - KRYS
globenewswire.com · Nov 17
Revolution Medicines (NASDAQ:RVMD) vs. Krystal Biotech (NASDAQ:KRYS) Head-To-Head Survey
defenseworld.net · Nov 11
Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Now Rated “Moderate Buy” by Wall Street Analysts
defenseworld.net · Nov 7
Krystal Biotech Analyst Says Stock Weakness 'Overblown'
benzinga.com · Nov 2
Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 2
Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates
zacks.com · Nov 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 16, 2026 · Live quote · Not investment advice